Select the drug indication to add to your list


Only 4 drugs may be compared at once

Generic Name and Formulations:

Brimonidine tartrate 0.33%; topical gel; contains propylene glycol.

Select therapeutic use:

Indications for MIRVASO:

Persistent (nontransient) facial erythema of rosacea.


≥18yrs: apply a pea-sized amount once daily to each of the five areas of the face (forehead, chin, nose, each cheek); spread gel smoothly and evenly in a thin layer. Wash hands after use.


<18yrs: not established.


Not for oral, ophthalmic, or intravaginal use. Avoid eyes, lips, irritated skin, or open wounds. Depression. Cerebral or coronary insufficiency. Raynaud's phenomenon. Orthostatic hypotension. Thrombangiitis obliterans. Scleroderma. Sjögrens syndrome. Severe or unstable cardiovascular disease. Pregnancy (Cat.B). Nursing mothers: not recommended.


Caution with beta-blockers, other antihypertensives, cardiac glycosides. Consider possibility of additive effects with CNS depressants (eg, alcohol, barbiturates, opiates, sedatives, anesthetics). Concomitant MAOIs may affect the metabolism and uptake of circulating amines; caution.

Pharmacological Class:

Alpha-2 agonist.

Adverse Reactions:

Erythema, flushing, burning sensation, contact dermatitis; systemic adverse reactions (eg, bradycardia, hypotension, dizziness), local vasomotor reactions (eg, pallor and excessive whitening, hypersensitivity [discontinue if significant]).

Generic Availability:


How Supplied:

Gel—30g (tube or pump), 45g (tube)

MIRVASO 30g of 0.33% tube of gels (Qty:1)

appx. price $453.00